Akston Biosciences Corporation is a pet biotechnology company engaged in the development and commercialization of biopharmaceutical products for cats, dogs, and other companion animals. It develops the Ambifect technology platform designed to harness the animal’s own cells to produce therapeutic levels of targeted antibodies. It develops a crystallizable fragment (Fc)-fusion protein platform to develop and manufacture new classes of biologic therapeutics for type 1 diabetes prevention, ultra-long-acting insulin therapy, and vaccines. It focuses on the development and manufacturing of protein therapeutics for the pet healthcare industry. It also provides contract development and manufacturing organization (CDMO) services for other animal health companies. The company was incorporated in 2011 and is based in Beverly, Massachusetts.